Clarity Pharmaceuticals Ltd (ASX:CU6)

Market Cap	967.87M +27.1%
Revenue (ttm)	10.58M -1.8%
Net Income	-96.35M
EPS	-0.28
Shares Out	372.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,826,400
Average Volume	2,082,750
Open	2.920
Previous Close	2.900
Day's Range	2.580 - 2.965
52-Week Range	1.840 - 5.870
Beta	1.20
RSI	42.37
Earnings Date	May 27, 2026

About Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 88
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CU6

Financial Performance

In fiscal year 2025, Clarity Pharmaceuticals's revenue was 9.46 million, a decrease of -17.76% compared to the previous year's 11.51 million. Losses were -64.30 million, 51.9% more than in 2024.